Table 2.

Association between prescription patterns and decrease in iPTH

Prescription PatterniPTHUnadjusted Model(4048 Sets)Adjusted Modelc(4029 Sets)
CinacalcetVDRASets (n)ACa (pg/ml)Proportionb (%)PD95% CIPD95% CI
NotDecreased561−67.845.80.00−0.05 to 0.050.01−0.03 to 0.06
NotStable2153−56.745.3ReferenceReferenceReferenceReference
NotIncreased755−127.660.30.140.09–0.180.130.09–0.17
StartingDecreased131−141.861.80.150.07–0.240.190.10–0.28
StartingStable307−205.167.40.220.16–0.270.250.19–0.31
StartingIncreased141−266.880.90.340.27–0.400.340.25–0.42
  • iPTH, intact parathyroid hormone; VDRA, vitamin D receptor activator; AC, absolute change; PD, proportion difference; 95% CI, 95% confidence interval.

  • a Means of AC in iPTH between reference and outcome visits.

  • b Proportions of patients with decrease in iPTH.

  • c Adjusted for age, sex, dialysis duration, iPTH levels, phosphorus levels, calcium levels, use of calcium- or non-calcium–based phosphate binders, single-pool Kt/V, and dialysate calcium.